Geroscience认为,分子驱动因素是衰老过程的基础。老年疗法需要一些策略来对抗衰老的分子驱动因素,以减少它们引发的慢性疾病和老年综合征。尽管用于预防的老年疗法的概念引起了很多兴奋,对"健康"的老年人开处方可能有害的药物的影响与许多延误有关。对安全和有效终点的担忧导致了滞留。相比之下,作为治疗疾病的新方法,实施具有老年病学特性的药物试验相对容易。在这些应用中,当治疗益处被认为超过疾病的危害时,药物的风险更容易证明。同样,有效的疾病治疗指标通常被认为比健康延长指标更可靠和可量化。总的来说,阐明疾病治疗应用中的老年学机制为推进转化老年学提供了关键机会,尤其是预防性老年科学试验经常受到阻碍。在这次审查中,canakinumab的治疗益处,胆水仙碱,和唑来膦酸作为疾病管理的一部分被考虑。还讨论了长寿诊所和其他促进翻译老年学的机会,作为当代护理的一部分。
Geroscience posits that molecular drivers underlie the aging process.
Gerotherapeutics entail strategies to counter molecular drivers of aging to reduce the chronic diseases and geriatric syndromes they trigger. Although the concept of
gerotherapeutics for prevention has generated much excitement, the implications of prescribing potentially harmful medications to older adults who are \"healthy\" have been associated with many delays. Concerns regarding safety and valid endpoints have contributed to holdups. In contrast, it has been relatively easier to implement trials of medications with gerotherapeutic properties as novel approaches to remedy disease. In these applications, the risks of the medications are easier to justify when therapeutic benefits are perceived as outweighing the harms of the disease. Likewise, metrics of effective disease treatments are often seen as more reliable and quantifiable than metrics of health prolongation. Overall, clarifying geroscience mechanisms in disease therapeutic applications provides key opportunities to advance translational geroscience, especially as preventive geroscience trials are often encumbered. In this review, gerotherapeutic benefits of canakinumab, cholchicine, and zoledronic acid as parts of disease management are considered. Longevity Clinics and other opportunities to advance translational geroscience as parts of contemporary care are also discussed.